학술논문
P49 MAGELLAN-1, PART 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure
Document Type
article
Author
Source
Journal of Virus Eradication, Vol 3, Iss , Pp 28-29 (2017)
Subject
Language
English
ISSN
2055-6640